The Financial Disclosure was omitted from the Letter “Diagnosis and Treatment for Stress Urinary Incontinence” by Vincent R. Lucente and Sonya N. Ephraim (Obstet Gynecol 2015;125:979). The correct statement is: “Financial Disclosure: Dr. Lucente has been a speaker for and has conducted research for Allergan; he has been a consultant, conducted research, and has been a speaker for AMS and Coloplast; and he has been a consultant for Medtronics. He also provides expert witness services to Bard and Coloplast. The other author did not report any potential conflicts of interest.” The Editorial Office regrets this error.
There are errors in the article, “Factors Associated With Seeking Treatment for Urinary Incontinence During the Menopausal Transition” by L.E. Waetjen, G. Xing, W.O. Johnson, J. Melnikow, and E.B. Gold (Obstet Gynecol 2015;125:1071–9). The first sentence of the abstract, Results, reads: “A total of 1,550 women (68% of women with UI) reported seeking treatment for UI over the 9 years of this study.” The correct sentence is: “A total of 706 women (46% of women with UI) reported seeking treatment for UI over the 9 years of this study.” Also, on page 1074, the second sentence in the Results section reads: “Of these women who reported UI, a total of 1,520 (68%) reported seeking UI treatment, most between baseline and year 9 (Fig. 1).” The correct sentence is: “Of these women who reported UI, 706 women (46%) reported seeking UI treatment, most between baseline and year 9.” The authors regret these errors.